Evofem announces FDA Orange Book listing of two additional U.S. patents

Evofem Biosciences announced that two additional U.S. patents which cover Phexxi and its labeled indication are now listed in the U.S. Food and Drug Administration publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. "The Orange Book listing of these two patents covering Phexxi’s composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. "We plan to further expand our intellectual property estate in the U.S. and overseas as we continue to iterate our vaginal pH modulator platform and seek entry into global markets." The newly listed U.S. Patent No. 11,337,989 covers contraception using the L-Lactic Acid Phexxi formulation. The ‘989 patent was issued by the U.S. Patent and Trademark Office on May 24, 2022 and is expected to expire in March 2033. The newly listed U.S. Patent No. 11,439,610covers compositions containing L-Lactic Acid, including the Phexxi formulation. The ‘610 patent was issued by the USPTO on September 13, 2022 and is expected to expire in March 2033.